Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets
Strengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the...